Summary

The North America parenteral nutrition market was valued at US$ 3,012.06 million in 2022 and is expected to reach US$ 4,805.31 million by 2030; it is estimated to record a CAGR of 6.0% from 2022 to 2030.

Rise in Prevalence of Gastrointestinal Diseases Fuels North America Parenteral Nutrition Market

Crohn's disease, bowel obstruction, ulcerative colitis, short bowel syndrome, microscopic colitis, and gastric cancer are a few examples of gastrointestinal diseases. According to the "Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study," published in January 2021, functional gastrointestinal disorders have affected over 40% of people across the globe.

Based on the Global Burden of Disease Study 2019, ~4.9 million cases of inflammatory bowel disease (IBD) were recorded worldwide in 2019. The US (762,890) registered the highest number of cases, with prevalence of 245.3 cases per 100,000 people, respectively. Ulcerative colitis and Crohn's disease are two of the commonly diagnosed IBDs. Crohn's disease is a complex, chronic disorder primarily affecting the digestive system. It is the most common disease in North America and Europe. As per the article titled "Understanding Short Bowel Syndrome: Current Status and Future Perspectives," published in 2020, the prevalence of short bowel syndrome (SBS) has increased by more than twofold in the last 40 years. The prevalence was ~30 cases per million in the US and approximately 1.4 cases per million in Europe.

Patients with gastrointestinal diseases are at an elevated risk of nutritional deterioration as they are asked to fast before undergoing diagnostic tests. They might also face nutritional deterioration due to therapeutic dietary restriction and loss of appetite caused by anorexia or altered nutritional requirements, which can be a result of the disease itself. Hence, medical nutrition is recommended for gastrointestinal disease patients as they are unable to ingest food. Further, the parenteral routes are preferred to provide them with essential nutrients. Some people might not show compatibility with tube insertion, which makes meeting their calorie and nutrient needs difficult. In such cases, parenteral nutrition is preferred to ensure their bodies remain hydrated and meet the calorie and other nutrient intake required to maintain physical well-being and function. Parenteral nutrition is indicated when patients cannot meet their nutritional needs as they are diagnosed with diseases such as cancer and chronic diseases, which affect the gastrointestinal tract. This type of nutrition is highly preferred as a therapy option for most patients suffering from severe SBS. Therefore, the growing prevalence of gastrointestinal diseases drives the parenteral nutrition market.

North America Parenteral Nutrition Market Overview

Cancer, heart disease, and other chronic diseases are the major causes of disability and death in the US. Per the National Center for Chronic Disease Prevention and Health Promotion, 6 in 10 people in the country are diagnosed with at least one chronic disease. Additionally, the American Hospital Association estimates that ~133 million people have at least one chronic disease, and that number is expected to reach 170 million by 2030. According to an article titled "Trends in Parenteral Nutrition," published in January 2019; on average, ~34,000 patients receive parenteral nutrition (PN) annually in the US. Enteral tube feeding can be prescribed for treating more than 350 disease conditions in children.

The US government is working on making people aware of enteral and parenteral nutrition through initiatives. For instance, the Feeding Tube Awareness Foundation creates awareness about the adoption of feeding tubes as a lifesaving medical intervention and helps parents of tube-fed children. The foundation celebrated the annual Feeding Tube Awareness Week from February 4, 2019, to February 8, 2019. In addition, a significant rise in US Food and Drug Administration (FDA) approvals of products by market players is likely to play a key role in the market growth during the forecast period. For instance, in March 2022, Fresenius Kabi received FDA approval for its SMOFlipid lipid injectable emulsion. The emulsion is the first and only four-oil lipid emulsion for patients of all ages requiring parenteral nutrition.

Therefore, the growing incidence of chronic diseases requiring medical nutrition, government efforts to raise awareness about the importance of parenteral nutrition, and strategic initiatives by key players support the growth of the parenteral nutrition market in the United States.

North America Parenteral Nutrition Market Revenue and Forecast to 2030 (US$ Million)

North America Parenteral Nutrition Market Segmentation

The North America parenteral nutrition market is segmented based on nutrient type, end user, and country. Based on nutrient type, the North America parenteral nutrition market is categorized into single dose amino acid solution, parenteral lipid emulsion, carbohydrates, trace elements, and vitamins & minerals. The single dose amino acid solution segment held the largest market share in 2022.

By end user, the North America parenteral nutrition market is segmented into hospitals, clinics, and others. The hospitals segment held the largest market share in 2022.

Based on country, the North America parenteral nutrition market is segmented into the US, Canada, and Mexico. The US dominated the North America parenteral nutrition market share in 2022.

ICU Medical Inc, Grifols SA, Pfizer Inc, Otsuka Pharmaceuticals Co Ltd, Baxter International Inc, B Braun SE, Fresenius Kabi AG, Aculife Healthcare Pvt Ltd, and Vifor Pharma Management AG are some of the leading players operating in the North America parenteral nutrition market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS

1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Parenteral Nutrition Market - Key Industry Dynamics
4.1 Market Drivers
4.1.1 Rise in Prevalence of Gastrointestinal Diseases
4.1.2 Surge in Cases of Malnutrition and Premature Births
4.2 Market Restraints
4.2.1 Mechanical, Gastrointestinal, and Metabolic Complications Associated with Parenteral Feeding Systems
4.3 Market Opportunities
4.3.1 New Product Developments by Companies
4.4 Future Trends
4.4.1 Innovation in Formulations of Nutrition Products
4.5 Impact Analysis
5. Parenteral Nutrition Market - North America Market Analysis
5.1 Overview
5.2 Parenteral Nutrition Market Revenue (US$ Mn), 2020 - 2030
6. North America Parenteral Nutrition Market Analysis - by Nutrient Type
6.1 Overview
6.2 Single Dose Amino Acid Solution
6.2.1 Overview
6.2.2 Single Dose Amino Acid Solution: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Parenteral Lipid Emulsion
6.3.1 Overview
6.3.2 Parenteral Lipid Emulsion: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Carbohydrates
6.4.1 Overview
6.4.2 Carbohydrates: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Trace Elements
6.5.1 Overview
6.5.2 Trace Elements: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Vitamins and Minerals
6.6.1 Overview
6.6.2 Vitamins and Minerals: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
7. North America Parenteral Nutrition Market Analysis - by End User
7.1 Overview
7.2 Hospitals
7.2.1 Overview
7.2.2 Hospitals: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Clinics
7.3.1 Overview
7.3.2 Clinics: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
8. North America Parenteral Nutrition Market - Country Analysis
8.1 North America: Parenteral Nutrition Market
8.1.1 North America: Parenteral Nutrition Market - Revenue and Forecast Analysis - by Country
8.1.1.1 United States: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
8.1.1.1.1 Overview
8.1.1.1.2 United States: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
8.1.1.1.3 United States: Parenteral Nutrition Market Breakdown, by Nutrient Type
8.1.1.1.4 United States: Parenteral Nutrition Market Breakdown, by End User
8.1.1.2 Canada: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
8.1.1.2.1 Overview
8.1.1.2.2 Canada: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
8.1.1.2.3 Canada: Parenteral Nutrition Market Breakdown, by Nutrient Type
8.1.1.2.4 Canada: Parenteral Nutrition Market Breakdown, by End User
8.1.1.3 Mexico: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
8.1.1.3.1 Overview
8.1.1.3.2 Mexico: Parenteral Nutrition Market - Revenue and Forecast to 2030 (US$ Million)
8.1.1.3.3 Mexico: Parenteral Nutrition Market Breakdown, by Nutrient Type
8.1.1.3.4 Mexico: Parenteral Nutrition Market Breakdown, by End User
9. Industry Landscape
9.1 Overview
9.1.1 Overview
10. Company Profiles
10.1 ICU Medical Inc
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 Grifols SA
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Pfizer Inc
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Otsuka Pharmaceuticals Co Ltd
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Baxter International Inc
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 B Braun SE
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Fresenius Kabi AG
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Vifor Pharma Management AG
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Aculife Healthcare Pvt Ltd
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
11. Appendix
11.1 About The Insight Partners
11.2 Glossary of Terms